Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers

References

• Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M. Lisdexamfetamine dimesylate: A new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs 2012; 26:691–705.
   PubMed Web of Science ®Google Scholar
• Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94:127–152.
   PubMed Web of Science ®Google Scholar
• Jasinski R, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009; 23:410–418.
   PubMed Web of Science ®Google Scholar
• LoVecchio F, Ozimek J, Sawyers B, Thole D. Outcomes after accidental pediatric ingestions of (dextro)amphetamine and methylphenidate. Am J Emerg Med 2009; 27:933–934.
   PubMed Web of Science ®Google Scholar
• Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: An open-label, dose-optimization study. J Child Adolesc Psychopharmacol 2009; 19:649–662.
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50:395–405.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Spyker DA, Cantilena LR, Bailey JE, Ford M. 2012 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol 2013; 51:949–1229.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Christian R, Saavedra LM, Wines R, Janas DE, Viswanathan M, et al.Attention-deficit/hyperactivity disorder: Identifying high priority future research needs. J Psychiatric Pract 2014; 20:104–117.
   PubMed Web of Science ®Google Scholar
• Bloom B, Jones LI, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey,2012. Vital Health Stat 10 2013; (258):1–81.
   Google Scholar
• U.S. Drug Enforcement Administration. Office of Diversion Control. National Forensic Laboratory Information System (NFLIS). (November 2012). Special Report: ADD/ADHD stimulants in NFLIS, 2007–2011. Springfield, VA.
   Google Scholar
• Torsoli A. Shire falls most since June on Adderall XR competition. BloombergBusiness. February 14, 2013. Available at: http://www.bloomberg.com/news/articles/2013–02-14/shire-profit-beats-estimates-amid-adderall-xr-sales-drop. Accessed 2/6/2015.
   Google Scholar
• Spiller HA, Hays HL, Aleguas A. Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity and management. CNS Drugs 2013; 27:531–543.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Montcrief S. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol 2007; 101:231–240.
   PubMed Web of Science ®Google Scholar
• Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 2014; 28:497–511.
   PubMed Web of Science ®Google Scholar
• Spiller HA, Griffith JRK, Anderson DL, Weber JA. Poison centers detect an unexpectedly frequent number of adverse reactions to lisdexamfetamine. Ann Pharmacother 2008; 42:1142–1143.
   PubMed Web of Science ®Google Scholar
• Chundru PG, Morgan DL, Borys DJ. Clinical effects and outcomes following unintentional double dose of lisdexamfetamine (Vyvanse) in pediatrics. Clin Toxicol 2010; 48:654. (abstract)
   Web of Science ®Google Scholar
• Akingbola OA, Singh D. Dexmedetomidine to treat lisdexamfetamine overdose and serotonin toxidrome in a 6-year-old girl. Am J Crit Care 2012; 21:456–459.
   PubMed Web of Science ®Google Scholar
• Meggs WJ, Cowan LR, Schmidt J, Riordilisi I, Rodriguez L. Benzodiazepine resistant sympathomimetic toxidrome responding to pentobarbital. Clin Toxicol 2010; 48:248. (abstract)
   Web of Science ®Google Scholar
• Spaziani ML, Schult RF, Wiegand TJ. Lisdexamfetamine ingestion resulting in hypertensive emergency treated with phentolamine. Clin Toxicol 2014; 52:406. (abstract)
   Web of Science ®Google Scholar
• Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio MJ. Potential trends in attention deficit hyperactivity disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 2013; 450–451: 242–249.
   PubMed Web of Science ®Google Scholar
• Cassidy TA, McNaughton EC, Varughese S, Russo L, Budman SH, Eaton TA, Butler SFB. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18–49: a national internet survey. J Atten Disord 2012 Dec 26 [Epub ahead of print].
   Web of Science ®Google Scholar
• Varughese S, Rosen S, Ertischek MD, Sembower MA, St. Jean E, Schnoll SH. Nonmedical use surveillance and signal identification of lisdexamfetamine dimesylate, a prodrug stimulant to treat ADHD. Am J Addict 2011; 20:373–374.
   Web of Science ®Google Scholar
• Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Open-Label, single-centre, Phase I study in healthy adult volunteers. Clin Drug Invest 2008; 28:745–755.
   PubMed Web of Science ®Google Scholar
• Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol 2007; 45:943–945.
   PubMed Web of Science ®Google Scholar
• Jaramillo JE, Marchbanks B, Willis B, Forrester MB. Evaluation of completeness of selected poison center data fields. J Med Syst 2010; 34:499–507.
   PubMed Web of Science ®Google Scholar